<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669965</url>
  </required_header>
  <id_info>
    <org_study_id>KRT-232-102</org_study_id>
    <nct_id>NCT03669965</nct_id>
  </id_info>
  <brief_title>KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera</brief_title>
  <official_title>A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kartos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kartos Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the&#xD;
      treatment of patients with phlebotomy-dependent polycythemia vera (PV). Inhibition of MDM2 in&#xD;
      PV is a new mechanism of action in PV. In Part A, patients must be resistant or intolerant to&#xD;
      hydroxyurea or have undergone treatment with interferon. In Part B, patients must be&#xD;
      resistant or intolerant to hydroxyurea.&#xD;
&#xD;
      This study is a global, open-label Phase 2a/2b study to determine the efficacy and safety of&#xD;
      KRT-232. In Part A of the study, patients will be randomly assigned to 5 arms with 2&#xD;
      different doses and 3 different dosing schedules of KRT 232. In Part B of the study, patients&#xD;
      will be randomized either to treatment with KRT-232 administered at the recommended dose and&#xD;
      schedule from Part A or to treatment with ruxolitinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with splenomegaly achieving a response at Week 32</measure>
    <time_frame>32 weeks</time_frame>
    <description>Response defined as having achieved both of the following:&#xD;
The absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32, with no more than one phlebotomy eligibility occurring post-randomization and prior to the Week 8 visit&#xD;
A reduction in spleen volume as assessed by MRI (or CT) ≥ 35% from baseline at Week 32</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response after achieving both the absence of phlebotomy eligibility and reduction in spleen volume (for patients with splenomegaly)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response after achieving phlebotomy independence</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of MPN-SAF TSS v2.0 patient-reported outcome</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of EORTC-QLQ-C30 patient-reported outcome</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of patients without splenomegaly achieving the absence of phlebotomy eligibility beginning at the Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post-randomization and prior to Week 8</measure>
    <time_frame>28 weeks</time_frame>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>Part A Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B KRT-232 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recommended KRT-232 dose and schedule from Part A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Ruxolitinib Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ruxolitinib per approved prescribing label</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Arm 4b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Arm 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRT-232</intervention_name>
    <description>KRT-232, administered by mouth</description>
    <arm_group_label>Part A Arm 1</arm_group_label>
    <arm_group_label>Part A Arm 2</arm_group_label>
    <arm_group_label>Part A Arm 2b</arm_group_label>
    <arm_group_label>Part A Arm 3</arm_group_label>
    <arm_group_label>Part A Arm 4b</arm_group_label>
    <arm_group_label>Part B KRT-232 Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib per approved prescribing label</description>
    <arm_group_label>Part B Ruxolitinib Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of PV (WHO 2016)&#xD;
&#xD;
          -  ECOG ≤ 2&#xD;
&#xD;
          -  Part A: patients with and without splenomegaly are eligible&#xD;
&#xD;
          -  Part A: patients must be resistant or intolerant to hydroxyurea or have undergone&#xD;
             treatment with interferon&#xD;
&#xD;
          -  Part B: only patients with splenomegaly are eligible&#xD;
&#xD;
          -  Part B: patients must be resistant or intolerant to hydroxyurea&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of post-PV myelofibrosis (IWG-MRT)&#xD;
&#xD;
          -  Prior treatment with MDM2 inhibitors, p53-directed therapies, HDAC, BCL 2 inhibitors&#xD;
&#xD;
          -  Splenic irradiation within 3 months prior to the first dose of study treatment&#xD;
&#xD;
          -  Clinically significant thrombosis within 3 months of screening&#xD;
&#xD;
          -  Grade 2 or higher QTc prolongation&#xD;
&#xD;
          -  Part B: prior treatment with a JAK inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Kirklin Clinic of UAB Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933 Cedex 09</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Haematologie - Onkologie - Hauptstelle</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Békés Megyei Központi Kórház Pándy Kálmán Tagkórház</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolnośląskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnoslaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki w Opolu</name>
      <address>
        <city>Opole</city>
        <zip>45-061</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Doctor Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>LAS Palmas</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

